A Study to Evaluate the Effects of Various Degrees of Hepatic Impairment on the Pharmacokinetics of A Single Subcutaneous Dose Of RO7434656, an Antisense Inhibitor of Complement Factor B

2023-508270-29-01 Protocol WA45032 Human pharmacology (Phase I) - Other Ended

Start 24 Sep 2024 · End 8 Oct 2025 · Status Ended · 3 EU/EEA countries · 4 sites · Protocol WA45032

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 36
Countries 3
Sites 4

Hepatic Impairment

Key facts

Sponsor
F. Hoffmann-La Roche AG
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Nutritional and Metabolic Diseases [C18]
Trial duration
24 Sep 2024 → 8 Oct 2025
Decision date (initial)
2024-07-31
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Hepatic Impairment

VersionLevelCodeTermSystem organ class
22.1 LLT 10052254 Hepatic impairment 10019805

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

F. Hoffmann-La Roche AG

Sponsor organisation
F. Hoffmann-La Roche AG
Address
Grenzacherstrasse 124
City
Basel
Postcode
4058
Country
Switzerland

Scientific contact point

Organisation
F. Hoffmann-La Roche AG
Contact name
Trial Information System - TISL

Public contact point

Organisation
F. Hoffmann-La Roche AG
Contact name
Trial Information System - TISL

Locations

3 EU/EEA countries · 4 investigational sites

By country

CountryMS statusPlanned subjectsSites
Germany Ended 8 1
Poland Ended 6 1
Slovakia Ended 22 2
Rest of world 0

Investigational sites

Germany

1 site · Ended
CRS Clinical Research Services Management GmbH
Clinical Pharmacology Unit, Board of Managing Directors, Lornsenstrasse 7, Brunswik, Kiel

Poland

1 site · Ended
Centrum Badan Klinicznych Piotr Napora Lekarze sp.p.
Centrum Badań Klinicznych Ośrodek Badań Wczesnej Fazy, Ul. Ul. Jana Dlugosza 4, 51-162, Wroclaw

Slovakia

2 sites · Ended
Summit Clinical Research s.r.o.
NA, Bardosova 2a, 831 01, Nove Mesto
Summit Clinical Research s.r.o.
NA, Duklianskych Hrdinov 34, 901 01, Malacky

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Germany 2024-10-29 2025-10-07 2024-10-29 2025-09-09
Poland 2024-10-07 2025-10-07 2024-10-07 2025-09-09
Slovakia 2024-09-24 2025-09-16 2024-09-26 2025-09-09

Application history

4 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-05-07 Germany Acceptable
2024-07-29
2024-07-31
2 SUBSTANTIAL MODIFICATION SM-1 2024-11-13 Acceptable 2025-01-10
3 SUBSTANTIAL MODIFICATION SM-2 2024-11-13 Germany Acceptable 2024-12-20
4 SUBSTANTIAL MODIFICATION SM-3 2024-11-15 Acceptable 2025-02-21